Sponsors (7)
The bill restructures NIAID into three focused institutes with set leadership terms to improve targeting and continuity for infectious, allergic, and immunologic research, but it risks short-term disruption and higher administrative costs that could reduce funds available for actual research.
Patients with infectious, allergic, or immunologic conditions and researchers will see more targeted research priorities and funding as work is assigned to distinct institutes focused on infectious, allergic, and immunologic diseases.
Scientists, public-health officials, and research administrators gain clearer institutional missions and program responsibility because responsibilities are split into dedicated institutes, making it easier to align work and avoid mission overlap.
Federal employees and institute leaders benefit from fixed, renewable 5-year director terms that can improve continuity of leadership and multi-year program planning.
Taxpayers and researchers risk reduced research funding because creating three separate institutes may raise administrative overhead and duplicate functions, diverting money away from grants and programs.
Federal employees, researchers, and health systems may face short-term administrative disruption as authorities, staff, and programs are shifted from NIAID to the new institutes, which could slow operations and coordination.
Researchers and patients could experience delays in research programs or funding decisions if terminating the current NIAID Director position and reorganizing creates leadership vacancies or transitional uncertainty.
Based on analysis of 2 sections of legislative text.
Splits NIAID into three institutes (Allergic, Infectious, Immunologic), creates separate institute statutes and directors (5-year terms, renewable once), and updates law references.
Creates three separate institutes from the current National Institute of Allergy and Infectious Diseases by dividing it into: a National Institute of Allergic Diseases, a National Institute of Infectious Diseases, and a National Institute of Immunologic Diseases. It adds new statutory sections and organizational entries, requires the NIH Director to oversee the new institutes until presidentially appointed directors are in place, ends the current Director position on enactment, and updates legal references across the Public Health Service Act.
Introduced February 21, 2025 by Charles Roy · Last progress February 21, 2025